Estimating COVID-19 risk in elderly GBM patients, page-2

Given that PI3K inhibitors may confer some protection against coronavirus infections, paxalisib would seem to be a safer therapy in the current environment for GBM patients. I noticed that recently there has been an investigator-initiated trial for PI3K inhibitor duvelisib (licensed to Verastem) to combat COVID-19 (https://clinicaltrials.gov/ct2/show/NCT04372602?term=duvelisib&draw=2&rank=1). As there have been cases of stroke and brain damage in even younger patients with COVID-19, it would be interesting to see if it might be an even better candidate for COVID-19 protection. Since Dr. Garner has been very good at getting investigator-initiated studies for other indications, I do believe it would be worthwhile to make the COVID research community aware of paxalisib to see if there is any interest in conducting such a study. Another investigator-initiated trial would only add more value to Kazia without distracting it from its current trials.